Tyr921
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Tyr921 - ITGB4 (human)

Site Information
LKVAPGYyTLTADQD    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: ITGB4 iso3 (mouse): Y923, ITGB4 (mouse): Y923, ITGB4 iso3 (human): Y921, ITGB4 iso2 (mouse): Y923, ITGB4 iso2 (human): Y921, ITGB4 (rat): Y923
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 5, 6, 7, 8)
Disease tissue studied: gastric cancer (1, 5, 7, 8), gastric carcinoma (1, 5, 7), leukemia (3), chronic myelogenous leukemia (3), liver cancer (2, 6), cholangiocellular carcinoma (2), hepatocellular carcinoma (6)
Relevant cell line - cell type - tissue: hepatocyte-liver (6), K562 (erythroid) (3), KATO III (gastric) (8), liver (2), MKN-45 (gastric) (1, 5, 7)




References

1

(2011) CST Curation Set: 11914; Year: 2011; SILAC: N; Biosample/Treatment: MKN-45(cell line)/normal; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

2

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

3

(2010) CST Curation Set: 9956; Year: 2010; SILAC: N; Biosample/Treatment: K562(cell line)/normal; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

(2010) CST Curation Set: 9475; Year: 2010; SILAC: N; Biosample/Treatment: liver(tissue)/untreated; Disease: liver cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

(2010) CST Curation Set: 9061; Year: 2010; SILAC: N; Biosample/Treatment: MKN-45(cell line)/DMSO; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

(2009) CST Curation Set: 7538; Year: 2009; SILAC: N; Biosample/Treatment: hepatocyte(liver)/untreated; Disease: liver cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 692-7
18180459   Curated Info

8

(2006) CST Curation Set: 1645; Year: 2006; SILAC: N; Biosample/Treatment: KATO III(cell line)/untreated; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.